亚研究02C:派姆单抗联合试验性药物或单独派姆单抗治疗III期黑色素瘤患者新辅助治疗的安全性和有效性(MK-3475-02C)

{"title":"亚研究02C:派姆单抗联合试验性药物或单独派姆单抗治疗III期黑色素瘤患者新辅助治疗的安全性和有效性(MK-3475-02C)","authors":"","doi":"10.31525/ct1-nct04303169","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9602,"journal":{"name":"Case Medical Research","volume":"144 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)\",\"authors\":\"\",\"doi\":\"10.31525/ct1-nct04303169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9602,\"journal\":{\"name\":\"Case Medical Research\",\"volume\":\"144 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Medical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31525/ct1-nct04303169\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31525/ct1-nct04303169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}